Juno acquires X-Body expansion antibody research and development technology reserve
June 05, 2015 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];
Tumor immunotherapy has become the most exciting achievement in the biomedical industry in recent years, and CAR-T therapy is one of the most popular star therapies. CAR-T therapy kills tumor cells by separating the patient's T cells in vitro and then re-injecting them into tumor patients by binding specific tumor antigens. Although no CAR-T therapy has officially entered the market today, it still cannot change the market's expectations.
One of the keys to CAR-T therapy is how to find an effective tumor target and identify it by synthesizing the corresponding antibodies. Therefore, the pharmaceutical giants entering the CAR-T market pay particular attention to research on antibody-related aspects.
Recently, Juno, a pioneer in the CAR-T field, has also reported mergers. The company acquired Massachusetts-based small biopharmaceutical company X-Body for $21 million in cash plus $23 million in stock. The company, which has only nine people, is focused on developing a range of full-length human antibodies for different targets. This has also been interpreted by the market as the company hopes to further consolidate its technical reserves in antibody research. In fact, Juno CEO Hans Bishop also attached great importance to the acquisition and said that with the addition of X-Body, the company will be better able to find new tumor antigens suitable for CAR-T therapy.
As the saying goes, "There is money to be willful." Since Juno completed an IPO totaling $265 million last year, the company has started the "buy, buy and buy" model. Last month, the company acquired Germany's Stage Cell Therapeutics to prepare for mass-produced CAR-T therapy products. At the same time, the company has also cooperated with heavyweight players in different fields such as Editas Medicine and Fate Therapeutics in gene editing and small molecule drug research and development. Original link:
Juno snaps up an antibody biotech amid CAR-T horse race
Erythritol For Chocolate,Zerose Erythritol,Lakanto Erythritol,Pure Erythritol Powder
Ningxia Eppen Biotec CO.,LTD , https://www.nxeppen.com